Bortezomib (Velcade®, Takeda Pharmaceutical Company Limited, Tokyo, Japan), a substance with a broad spectrum of biological actions, has been tested in the treatment of lymphoma, in which it acts through upregulation of the gene encoding phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) mediated by oxidative/endoplasmic reticulum stress- (also known as NOXA; a gene encoding phorbol-12-myristate-13-acetate-induced protein 1) and subsequent induction of apoptosis. This evidence concerns the gene PMAIP1 and lymphoma.